1. Home
  2. Analysis
  3. Amaryl
  4. Xigduo-xr

Amaryl and Xigduo xr drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 15 people who take Amaryl and Xigduo xr. Common interactions include diabetic ketoacidosis among females, and pain in extremity among males.

The phase IV clinical study analyzes what interactions people who take Amaryl and Xigduo xr have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2023

15 people who take Amaryl and Xigduo xr together, and have interactions are studied.

What is Amaryl?

Amaryl has active ingredients of glimepiride. It is used in diabetes. Currently, eHealthMe is studying from 32,043 Amaryl users.

What is Xigduo xr?

Xigduo xr has active ingredients of dapagliflozin propanediol; metformin hydrochloride. Currently, eHealthMe is studying from 2,589 Xigduo xr users.

Number of Amaryl and Xigduo xr reports submitted per year:

Amaryl and Xigduo xr drug interactions.

Common Amaryl and Xigduo Xr drug interactions by gender *:

female:

  1. Diabetic ketoacidosis
  2. Myocardial infarction
  3. Basedow's disease
  4. Bronchitis
  5. Cardiac arrest
  6. Circulatory collapse
  7. Coma
  8. Genital herpes
  9. Hypotension
  10. Ketoacidosis

male:

  1. Pain in extremity
  2. Sepsis
  3. Dyspnoea
  4. Emotional distress
  5. Genital abscess
  6. Genital lesion
  7. Headache
  8. Hepatic steatosis
  9. Hyperglycaemia
  10. Ischaemia

Common Amaryl and Xigduo Xr drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Diabetic ketoacidosis

40-49:

n/a

50-59:

  1. Anal abscess
  2. Depression
  3. Diabetic foot
  4. Emotional distress
  5. Genital abscess
  6. Genital lesion
  7. Hepatic steatosis
  8. Hyperglycaemia
  9. Necrotising fasciitis
  10. Pain

60+:

  1. Myocardial infarction
  2. Pain in extremity
  3. Coma
  4. Dyspnoea
  5. Headache
  6. Hypotension
  7. Ischaemia
  8. Ketoacidosis
  9. Nasal discharge discolouration
  10. Necrosis

Common conditions people have *:

  1. High Blood Pressure: 7 people, 46.67%
  2. Type 2 Diabetes: 6 people, 40.00%
  3. High Blood Cholesterol: 5 people, 33.33%
  4. Blood Glucose Abnormal: 2 people, 13.33%
  5. Pain: 2 people, 13.33%
  6. Weight Decreased: 1 person, 6.67%
  7. Hypotension (abnormally low blood pressure): 1 person, 6.67%
  8. Asthma: 1 person, 6.67%
  9. Constipation: 1 person, 6.67%
  10. Cough: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Amaryl and Xigduo xr?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Amaryl drug interactions:

Browse interactions between Amaryl and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xigduo xr drug interactions:

Browse interactions between Xigduo xr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on glimepiride and dapagliflozin propanediol; metformin hydrochloride (the active ingredients of Amaryl and Xigduo xr, respectively), and Amaryl and Xigduo xr (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Amaryl and Xigduo xr.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.